Drug Trial News

RSS

Arcturus and Duke-NUS announce approval of clinical trials for COVID-19 vaccine candidate

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, and Duke-NUS Medical School, Singapore's flagship research-intensive graduate entry medical school, today announced that the Clinical Trial Application for COVID-19 vaccine candidate LUNAR-COV19 has been approved to proceed by the Singapore Health Sciences Authority.

22 Jul 2020

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) issued a positive response to the Qualification Plan (QP) for glutamate dehydrogenase (GLDH) as a safety biomarker for drug-induced liver injury (DILI), developed by C-Path's Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC).

22 Jul 2020

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A new study published on the preprint server medRxiv by a research group from the U.S. and Germany indicates that a novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) induces functional and proinflammatory T cell responses in almost all participants – marking another landmark achievement for this promising vaccine candidate.

21 Jul 2020

Drug discovery pipeline to exploit transcription factors for cancer therapy

Cancer is a leading cause of death and one of the most complex challenges to modern medicine. By employing cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental process of transcription, the new start-up company QUANTRO Therapeutics strives to radically change the precision and scope of cell-based drug screening.

21 Jul 2020

UC Davis Health evaluates new antibody cocktail as a possible treatment for COVID-19

Timothy Albertson, chair of internal medicine and specialist in pulmonary and critical care, is leading efforts at UC Davis Health to test a new antibody cocktail (REGN-COV2) as a prevention and treatment for COVID-19.

20 Jul 2020

China's Ad5 vectored COVID-19 vaccine safe and induces immune response

A phase 2 trial of an Ad5 vectored COVID-19 vaccine candidate, conducted in China, has found that the vaccine is safe and induces an immune response, according to new research published in The Lancet.

20 Jul 2020

Oxford University and AstraZeneca vaccine against SARS-CoV-2 safe and induces immune response

Promising early stage results from a phase 1/2 clinical trial of the UK's vaccine candidate against SARS-CoV-2 (the virus that causes COVID-19) are published today in The Lancet.

20 Jul 2020

Oxford University and AstraZeneca to publish eagerly-anticipated COVID-19 trial results today

The coronavirus pandemic is still rapidly spreading across the globe, infecting more than 14.44 million people. With more than 188 countries and territories affected, scientists are racing to develop a vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).

19 Jul 2020

Hydroxychloroquine is not indicated for COVID-19 under any circumstances

The drug Hydroxychloroquine has long been studied as a treatment for malaria and autoimmune diseases. When the coronavirus pandemic spread across the globe, many countries resorted to using the drug in the hopes that it would improve outcomes of hospitalized patients affected by the coronavirus disease (COVID-19).

19 Jul 2020

Sanders-Brown researchers screen first participant in drug study to prevent early Alzheimer's

Researchers at the University of Kentucky's Sanders-Brown Center on Aging (SBCoA) recently screened the first participant in the world for what is known as the AHEAD 3-45 study.

17 Jul 2020

Avicenna.AI secures FDA clearance for its CINA Head neurovascular imaging artificial intelligence tool

Medical imaging AI specialist Avicenna.AI today announced it has received 510(k) clearance from the US Food and Drug Administration for its CINA Head triage AI solution for neurovascular emergencies.

17 Jul 2020

Compelling study shows heparin may protect against COVID-19

A compelling new study conducted by an international team of researchers has demonstrated that the widely used blood-thinning medication - heparin - can block infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

16 Jul 2020

Moderna vaccine induces robust immune response against SARS-CoV-2

The race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on, and one of the potential candidates shows promise in inducing an immune response.

15 Jul 2020

UC study tests efficacy of immune regulating drug in treating patients with COVID-19 pneumonia

Researchers at the University of Cincinnati are testing a commonly used drug, called sirolimus, to determine its safety and efficacy in treating hospitalized patients with COVID-19 pneumonia in the trial.

15 Jul 2020

New trial investigates if prostate cancer drug can be used to treat COVID-19

In a new trial, Swedish researchers will investigate if a medicine normally used to treat prostate cancer can also be used to treat COVID-19 in patients.

15 Jul 2020

Keck Medicine of USC participates in clinical trial to evaluate antiviral drug as possible COVID-19 treatment

Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial to evaluate the safety and efficacy of an antiviral drug, DAS181, as a possible treatment for hospitalized patients with severe COVID-19.

14 Jul 2020

UTHealth physicians investigate blood pressure drug's effect on improving COVID-19 outcomes

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston.

14 Jul 2020

7-day levofloxacin/dexamethasone eye drops as effective as standard treatment after cataract surgery

Santen EMEA and NTC are delighted to announce that the results of their phase III clinical study, LEADER7, have been published in Eye.

13 Jul 2020

Morinaga Milk’s probiotic B. breve A1 improves memory functions of older adults with MCI

Morinaga Milk Industry Co., Ltd., a leading Japanese dairy product company and a key global probiotics manufacturer, confirmed that its proprietary probiotic strain Bifidobacterium breve A1 (a.k.a. B. breve MCC1274) is safe and effective for improving memory functions of older adults with suspected mild cognitive impairment (MCI) in a randomized, double-blind, placebo-controlled trial (RCT).

10 Jul 2020

Upcoming phase II study to discover personalized therapy for patients at high risk for breast cancer relapse

Indiana University School of Medicine researchers Milan Radovich, PhD, and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple negative breast cancer are critical indicators for the prediction of disease recurrence and disease-free survival.

10 Jul 2020

Previous
1
...
79
80
81
82
83
84
85
...
1149
Next

Drug Trial News

Arcturus and Duke-NUS announce approval of clinical trials for COVID-19 vaccine candidate

Scientific evidence shows GLDH is a safe biomarker for drug-induced liver injury

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

Drug discovery pipeline to exploit transcription factors for cancer therapy

UC Davis Health evaluates new antibody cocktail as a possible treatment for COVID-19

China's Ad5 vectored COVID-19 vaccine safe and induces immune response

Oxford University and AstraZeneca vaccine against SARS-CoV-2 safe and induces immune response

Oxford University and AstraZeneca to publish eagerly-anticipated COVID-19 trial results today

Hydroxychloroquine is not indicated for COVID-19 under any circumstances

Sanders-Brown researchers screen first participant in drug study to prevent early Alzheimer's

Avicenna.AI secures FDA clearance for its CINA Head neurovascular imaging artificial intelligence tool

Compelling study shows heparin may protect against COVID-19

Moderna vaccine induces robust immune response against SARS-CoV-2

UC study tests efficacy of immune regulating drug in treating patients with COVID-19 pneumonia

New trial investigates if prostate cancer drug can be used to treat COVID-19

Keck Medicine of USC participates in clinical trial to evaluate antiviral drug as possible COVID-19 treatment

UTHealth physicians investigate blood pressure drug's effect on improving COVID-19 outcomes

7-day levofloxacin/dexamethasone eye drops as effective as standard treatment after cataract surgery

Morinaga Milk’s probiotic B. breve A1 improves memory functions of older adults with MCI

Upcoming phase II study to discover personalized therapy for patients at high risk for breast cancer relapse

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News